chang recommend
upgrad outperform
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
ugli epacadostat mostli behind us clariti olumi return
construct outlook share upgrad stock outperform believ
valu jakafi end patent exclus potenti gener meaning cash flow
pipelin success path valu extract time adequ reflect
share simpli much potenti valu embed late stage portfolio ignor
jakafi one remain uniqu growth asset entrench posit littl
way commerci threat decad grow presenc monopoli afford price
power domin mpn market uniqu durable/sustain growth outlook
remain cautiou commerci outlook olumi sinc box
dose platelet concern battl jak powerhous
rheumatolog there enough pipelin could yet bear fruit -- may
abl find altern way monet jakafi revenu stream
return prior thesi compani inde thought increasingli
diversifi approach innov oncolog although lack obviou break-out asset carri
flag beyond jakafi investor compani becam overli distract chase ido pipe
dream reput damag mani revers time pipelin still hold
singl doubl plenti year expand unless strateg option emerg sooner
compani host analyst event coupl week good opportun showcas
capabl
like jak portfolio includ new jakafi indic gvhd essenti
thrombocytosi itacitinib earlier-stag gvhd potenti even expand olumi
new autoimmun indic maxim valu asset within competit class
interest program like fgfr inhibitor bladder cancer
cholangiocarcinoma mpn could ultim drive hundr million peak
annual sale perhap depend competit dynam program look
differenti dlbcl field crowd mechan propens toward
coliti limit commerci potenti brd pim target highli specul
hope compani better time
compani origin core capabl medicin chemistri dont see
develop antibodi target gitr like rest
cancer i/o field compani core compet domain
see littl threat jakafi celg jak inhibitor trail develop
timelin clinic profil
particularli interest comparison inci valuat vs mdglmost investor find
puzzl comp given vastli differ stage develop busi structur
therapeut foci interest overlap consider approach
valuat vs inci gap closer would expect flagship asset
loss patent protect toward end next decad possibl sooner
cours ceo previous ceo higher
valuat offer fulli derisk asset well way peak revenu potenti robust
broad pipelin royalti ex-u jakafi nv capmatinib also seem clearli way
toward meaning sustain profit still see upsid pt
clearli mani other see even upsid consid recent secondari placement
also recogn nash asset still navig trial fda approv despit
linger investor question suitabl dose maintain clean profil one
remain ahead emerg class fxr agonist pparsand point still
much patent life left jakafi rel speak hard see one
would consid meaning higher convict opportun
upgrad dovetail recent weekend muse sustain growth compani
invest higher revenu deriv higher valuat especi
strong return despit epacadostat failur still favor view compani
scientif leadership abil gener least modest return invest
end make dramat chang valuat model assumpt
instead assum rapid margin expans under-invest minim
termin growth increas spend match net incom lower ep
estim meaning rais termin growth outlook consid
compani ep compound-annual-growth-rate earli next decad would seem
reason conserv assumpt lower olumi estim
maintain jakafi modestli increas captur line includ entir
consensu jakafi offset below-consensu
estim royalti revenu due conserv assumpt olumi
total revenu estim vs consensu
slightli ep estim vs consensu
meaning consensu invest vs
long term three path forward
maintain high spend rel net incom hope creat life jakafi
ramp expand margin meaning becom valu compani
failur epacadostat olumi semi-crippl dose approv us
platelet concern clock gradual tick patent expiri think option like prove
viabl compani yet opportun hoard cash lofti
valuat becom acquir new program compani may instead seek maxim valu
sharehold altern mean
pt base dcf use discount rate appli commerci stage
biotech compani termin growth rate includ contribut jakafi et gvhd well olumi
also includ meaning gener catch-al line item captur program fgfr inhibitor inhibitor
valuat methodolog price target deriv dcf analysi model
assum termin growth rate discount rate higher use larg cap biotech
reflect addit development risk associ compani
downsid risk includ increas competit threat jakafi/olumi continu aggress develop spend
jakafi patent expiri draw near
risk mdgl valuat depend upon complet clinic trial safeti still need valid
longer larger clinic trial compani intellectu properti relat may unabl protect new gener
entrant beyond plu hatch waxman extens earlier mani therapeut area develop
program highli competit either number therapi develop market compani limit financ
requir subsequ equiti rais dilut includ model
articl articl
time dissemin june et
analyst josh schimmer steven breazzano maneka mirchandaney ami liu shenston huang primarili respons
prepar research report attest follow view opinion render research report reflect
person view subject compani issuer part research analyst compens directli
relat specif recommend view research report
